AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00571363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mohs micrographic surgery
Description: excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
Study NCT04374825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: This intervention consists of 8, 90-minute online group sessions delivered via video conference. Content will be developed by tailoring an ACT intervention to the specific needs of women with MBC, by using qualitative data gathered in patient focus groups. The intervention will incorporate key concepts of ACT (i.e., creating meaning and purpose in life via coping skills, activities in line with patients' values, and mindfulness meditation).
Study NCT04374825 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Stress Management (CBSM)
Description: This intervention consists of 8, 90-minute online group sessions delivered via videoconference. Content is drawn from a standard published CBSM intervention previously tested in other studies. The intervention incorporates key concepts of CBSM (i.e., managing stress via deep breathing and relaxation, identifying distorted thoughts,cognitive restructuring, and effective interpersonal communication).
Study NCT03434197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esflurbiprofen
Description: A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
Study NCT03434197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac diethylamine
Description: A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
Study NCT02589405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide
Study NCT02589405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermotivin® Soft Liquid cleanser
Study NCT02589405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil® Dermacontrol Moisturizer SPF30
Study NCT04467320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques
Description: Teaching Recovery Techniques is a 7-session group programme, with 5-sessions for the young person and 2-sessions for the carer. All sessions will be held online. The carer sessions are focused on psychoeducation around trauma and PTSD, as well as skills for supporting a young person through the intervention and with PTSD symptoms more broadly. The young person sessions are primarily focused on skill building and include: psychoeducation and understanding intrusive memories; intrusive images, worries and dreams; arousal, emotions, relaxation and coping; avoidance and triggers; and, memories.
Study NCT04467320 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: In the care as usual arm, social workers will follow their standard care protocol for young people experiencing psychological distress. A typical response may include a referral to either the specialist local CAMHS or general CAMHS.
Study NCT00003317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Study NCT00003317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00003317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Study NCT00003317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00003317 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00003317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Study NCT02905149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serrato
Description: Serratus plane block.
Study NCT02905149 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard anesthesia
Study NCT03812120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural closure with L-PRF
Description: Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF) as an adjunct for dural repair
Study NCT03812120 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dural closure with classical fibrin sealants
Description: Evaluation of the safety and effectiveness of classical fibrin sealants as an adjunct for dural repair
Study NCT00169754 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mapping kidney anatomy
Description: videotape of surgical procedure to document location of attached stones and condition of calyces and papilla.
Study NCT03301701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Description: Radical prostatectomy
Study NCT03301701 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR (19Gy) or SBRT (35-40Gy)
Description: Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT
Study NCT03821909 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound-guided protal venous blood sampling
Description: We wil obtain portal venous blood samples via endoscopic ultrasound(EUS) in patients with suspected pancreatic masses.
Study NCT03330288 — intervention group
Intervention type: DRUG
Intervention: Theraflex, BAY 874017
Description: The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day
Study NCT00203073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate 20 mg
Description: glatiramer acetate 20 mg
Study NCT00203073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate 20 mg, with mitoxantrone
Description: glatiramer acetate 20 mg, with mitoxantrone
Study NCT01173354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Free balanced amino acid mixture
Description: 7 g free amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 24% is leucine.
Study NCT01173354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Free essential amino acid mixture
Description: 7 g free essential amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 40% is leucine.
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Given PO
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Given PO
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Given PO
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Given via injection
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given via injection
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: intravenous
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Description: Given PO
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Given PO
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given SC
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histrelin Acetate
Description: Receive SC
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histrelin Acetate
Description: Receive SC
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Receive SC or IM
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Receive SC or IM
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilutamide
Description: Given PO
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilutamide
Description: Given PO
Study NCT03678025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orchiectomy
Description: Undergo bilateral orchiectomy
Study NCT03678025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Description: Undergo bilateral orchiectomy
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT03678025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03678025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03678025 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard radiation
Study NCT03678025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Standard surgery
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: injection
Study NCT03678025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: injection
Study NCT04633577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: A bolos of 1.5mg/kg lidocaine will be administered before induction. Then, infusion of 4mg/kg/h lidocaine will maintain during procedure.
Study NCT04633577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: 0.9% normal saline
Study NCT02653183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Comparator: Aquacel Surgical
Description: Post-operative all-in-one self-adherent soft silicone coated foam dressing. Duration of treatment: Total 5 days included the day of surgery and 4 post-operative days.
Study NCT02653183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Mepilex Border Post-Op
Description: Aquacel Surgical is a sterile, one piece post-operative dressing.Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days.
Study NCT01719783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAIV H5N2
Description: 2 doses provided intranasally
Study NCT01719783 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo provided intranasally
Study NCT00885053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks
Study NCT00885053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
Study NCT02676115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Post Operative Skin Care
Description: Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
Study NCT01385865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract
Description: 18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks
Study NCT01385865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
Study NCT05939557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jones technique
Description: is a gentle soft tissue manipulation consisting of a passive procedure that positions the body in a position of comfort to release tissue that compresses or shortens the body structure (muscle contraction and joint dysfunction)
Study NCT05939557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: KT has an S-shaped glue, which lifts the skin, thus improving blood and lymphatic circulation, with the intention of relieving pain and improving musculoskeletal diseases especially in sports
Study NCT04381494 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Multiparametric Mobile Technology
Description: Using a spirometer, an armband, and a tablet to collect data.
Study NCT00465751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chenodeoxycholic acid
Description: chenodeoxycholic acid 500 mg capsules tid po
Study NCT00465751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: placebo capsules containing mannitol tid po
Study NCT00003317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT04172324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIBBOT
Description: Hibbot is an assistive mechanical device, lightweight and portable. The mechanism of the Hibbot manages to control all degrees of freedom (3x rotation and 3x translation) at the level of the pelvis and lower trunk. The goal is to maximize a child's own muscle activity and postural control while giving as minimal support as needed.
Study NCT01760291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN LAA Closure Technology
Study NCT04315454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: A group of patients will receive 20 ml of normal saline into the interfascial plane between rhomboids major \&erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side, the other group of patients will receive 20 mg 0.25% Levobupivacaine bilaterally as above 10 mg each side.
Study NCT04315454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: A group of patients will receive 20 ml of normal saline into the interfascial plane between rhomboids major \&erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side, the other group of patients will receive 20 mg 0.25% Levobupivacaine bilaterally as above 10 mg each side.
Study NCT04172324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard care involves the standard physiotherapy the child would get during clinical care.
Study NCT04172324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care involves the standard physiotherapy the child would get during clinical care.
Study NCT01802229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic mesh placement
Description: Placement of a Omega 3 mesh, fixed to the border of the fascia
Study NCT01802229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial suture
Description: The port-site hole is closed with simple suture of the fascia
Study NCT04208243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creative Arts Therapy
Description: The intervention will consist of approximately weekly CAT in the infusion center during cancer therapy. The interventionist is a Master's prepared, licensed dance/movement therapist who is experienced in music and art therapies as well. The CAT includes dance/movement such as playing with a parachute, simple yoga breathing and postures, and work with physioballs. The music includes singing, listening to music, and playing instruments. The art consists of drawing, finger painting, working with clay. The CAT may occur in individual sessions in private infusion rooms, or in groups in the middle of the infusion center. The CAT is not only a distraction, but also a therapeutic process addressing the stressors of cancer and its treatment. The dose of CAT will be recorded (number and type of sessions) and will be factored into the analysis.
Study NCT02321306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001
Description: LUM001 administered orally once each day.
Study NCT03721016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L
Description: MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
Study NCT02676115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medipore Tape
Description: * One layer of Medipore tape will be placed across the incision.~* Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.~When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken.
Study NCT00113087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril to target dose of .4mg/kg/day divided to twice per day (BID)
Study NCT00113087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo
Study NCT02387931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Nature Made Vitamin D 2000IU, 1 softgel taken daily
Study NCT02387931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
Study NCT03721016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
Study NCT03721016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
Study NCT00009984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00009984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study NCT02387931 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, 2 taken daily
Study NCT02761733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving Patient Outcomes toward Wellness and Recovery (mPOWR)
Description: An mPOWR intervention and toolkit that consists of strategies, prompts, and decision aids designed to foster patient involvement in treatment. The mPOWR intervention includes a questionnaire that assesses quality of life and consumer functioning for use in the development of consumer-centered goals and outcomes within the mPOWR intervention.
Study NCT03550664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring of neuromuscular transmission
Description: Monitoring of neuromuscular transmission will be done by TOFScan (IdMed, Marseille, France). This device is CE marked, and is used routinely in daily clinical practice. Prior to induction of anesthesia, the TOFScan is placed on a patient's hand and the two stimulation electrodes (ECG electrodes) are placed at the level of the ulnar nerve at the wrist. After induction of anesthesia and before administration of a curare, the TOFScan is calibrated according to the manufacturer's instructions. The TOFScan is placed in automatic mode, it will then automatically adapt its mode of stimulation to the depth of the curarization. The TOFScan measurements will be recorded on a PC connected to the TOFScan.
Study NCT04402060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-9
Description: Complement (C3) Inhibitor
Study NCT04402060 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: Normal saline of equal volume to active arm
Study NCT04198597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: Please see arm/group descriptions
Study NCT04198597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process-based Cognitive Behavioral Therapy
Description: Please see arm/group descriptions
Study NCT01379287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iso-Fludelone
Description: Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.
Study NCT00120523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 %
Study NCT03558139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study NCT00120523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroids
Description: TCS
Study NCT04569656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrolyzed guar gum
Description: treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg for 6 weeks
Study NCT04945577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory Parameters
Description: Laboratory measurement of patient's inflammatory status in unit of % and mg/dl